| The FDA's official policy changes following the advisory panel's recommendations on compounded peptide therapies are expected to provide clarity on regulatory pathways for these solutions. | Q3 2026 | 2026-07-27 | 2026-09-30 | This catalyst directly impacts regulatory certainty and market access for peptide-based solutions, a key growth area for medical optimization providers like Hims & Hers, and influences the broader GLP-1 market landscape for companies such as Eli Lilly and Novo Nordisk. | Theme | theme_composer | HIMS, LLY, NVO | 3 | 15.0058 | 1.18 | 1.0 | Regulatory/Policy | 1.35 | 2390.4185 | 2026-09-01 | False | 2 | 0.687 | 109.4433 | Theme composer | | | |
| The ongoing legal proceedings and potential outcomes of the FTC's complaint filed against Hims & Hers regarding billing, cancellations, and data sharing practices. | Ongoing, likely extending into 2027 | 2026-07-29 | 2027-12-31 | The resolution of this FTC complaint could establish important precedents for regulatory oversight in the telehealth and digital health industry, impacting operational practices, consumer trust, and compliance requirements for other technology-enabled wellness platforms within the 'Optimizers' theme. | Theme | theme_composer | HIMS, DXCM, ODD | 3 | 4.501 | 1.18 | 0.85 | Regulatory/Policy | 1.35 | 609.4578 | 2026-09-01 | False | 2 | 0.4091 | 55.3891 | Theme composer | | | |
| CMS is expected to announce its coverage decision for Continuous Glucose Monitoring (CGM) in Type 2 non-insulin diabetes patients. | Before end of 2026 | 2026-09-01 | 2026-12-31 | This decision would significantly expand Dexcom's addressable market in the U.S. by including approximately 25 million Type 2 non-insulin patients, driving substantial long-term revenue growth and solidifying CGM as a standard of care, aligning with the theme's focus on proactive, data-driven health. | Ticker | theme_composer | DXCM | 1 | 0.0005 | 1.18 | 0.92 | | 1.0 | 0.0593 | 2026-09-01 | False | 1 | 0.0062 | 0.6708 | Theme composer | | | |
| First readout of Ziltivekimab from the ZEUS Phase III trial for ASCVD. | Q3 2026 | 2026-07-01 | 2026-09-30 | This is a high-potential, first-in-class anti-IL-6 treatment for ASCVD, with positive results potentially opening a large new market and validating a new mechanism of action. | Ticker | | | | | | | | | | | | | | | NVO (ticker) | NVO_af1c28d8 | 2026-05-06 | earnings_transcript |
| Rollout of Premier Protein 42-gram Ultimate Shake and Premier Protein Sparkling Soda to mass, food, and e-commerce channels. | rolling out to mass, food and e-commerce channels this quarter (Q4 FY26) | 2026-07-01 | 2026-09-30 | These innovations expand the product portfolio into new performance and refreshment categories, creating new opportunities to reach consumers and drive incremental distribution. | Ticker | | | | | | | | | | | | | | | BRBR (ticker) | BRBR_16bc057d | 2026-08-04 | earnings_transcript |
| Major promotional events in Q4 FY26, including a promotional event with a mass retailer and repeating Q4 club promotions. | fourth quarter (Q4 FY26) | 2026-07-01 | 2026-09-30 | These promotional activities are designed to deliver significant household gains, including new-to-category consumers, and are expected to boost volume, though they may impact price/mix. | Ticker | | | | | | | | | | | | | | | BRBR (ticker) | BRBR_e5b6f97a | 2026-08-04 | earnings_transcript |
| Gross margin normalization to the low-50% range as integration benefits, cost savings, and tariff effects align. | Back half of 2026 | 2026-07-01 | 2026-12-31 | A sustained margin recovery into the low-50s would substantially improve profitability and free cash flow, reducing margin headwinds from the 2025 integration period. | Ticker | | | | | | | | | | | | | | | CELH (ticker) | CELH_a81d1569 | 2026-02-26 | earnings_transcript |
| CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data. | before the end of this year | 2026-08-07 | 2026-12-31 | This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers. | Ticker | | | | | | | | | | | | | | | DXCM (ticker) | DXCM_e0606eaf | 2026-07-30 | earnings_transcript |
| Appointment of a new permanent CEO for Lululemon Athletica Inc. | until the next CEO steps into their role | 2025-12-11 | 2026-12-31 | A new CEO will set the long-term strategic direction, potentially impacting product strategy, market expansion, and overall company culture, which could significantly influence investor sentiment and future performance. | Ticker | | | | | | | | | | | | | | | LULU (ticker) | LULU_ba44673d | 2025-12-11 | earnings_transcript |
| Lululemon's 'action plan' to drive inflection in its U.S. business, including a strong new product pipeline and increasing new style penetration to 35% by Spring 2026, with a focus on updating key franchises and introducing new innovations. | beginning in spring 2026 and continue to strengthen throughout the year | 2026-03-01 | 2026-12-31 | The success of this product refresh and activation is crucial for reversing the negative revenue trends in the U.S. and improving customer engagement, directly impacting sales, market share, and investor confidence. | Ticker | | | | | | | | | | | | | | | LULU (ticker) | LULU_61707124 | 2025-12-11 | earnings_transcript |
| Lululemon's ability to mitigate the financial impact of higher tariffs and the removal of the de minimis provision through strategic pricing, supply chain initiatives (vendor negotiations, DC network efficiency), and enterprise-wide savings. | first full year of tariffs | 2026-02-02 | 2027-01-31 | The success of these mitigation efforts will directly impact gross and operating margins, which are expected to face pressure in 2026 due to these increased costs. | Ticker | | | | | | | | | | | | | | | LULU (ticker) | LULU_ddabcb38 | 2025-12-11 | earnings_transcript |
| Lululemon's evaluation and potential repositioning of its distribution center network, particularly regarding a large Canadian DC, in response to the removal of the de minimis provision. | as we move into '26 and the team is further along in that work stream | 2026-02-02 | 2026-12-31 | Changes to the DC network could impact supply chain efficiency, logistics costs, and inventory management, directly affecting operating expenses and the ability to serve markets effectively. | Ticker | | | | | | | | | | | | | | | LULU (ticker) | LULU_891f0fc7 | 2025-12-11 | earnings_transcript |
| Lululemon's ability to maintain strong revenue growth and momentum in China Mainland, especially after calendar shifts impacting Q4 2025, and continued market penetration across city tiers. | for the year | 2026-02-02 | 2027-01-31 | China Mainland is Lululemon's second-largest market and a significant growth driver. Sustained strong performance is critical for overall revenue growth and international expansion goals. | Ticker | | | | | | | | | | | | | | | LULU (ticker) | LULU_e6f9ab68 | 2025-12-11 | earnings_transcript |
| Lululemon's ability to manage operating margins in fiscal year 2026, given expected pressures from a full year of increased tariffs and the removal of de minimis, partially offset by efficiency initiatives and potential expense savings. | as we look into '26 | 2026-02-02 | 2027-01-31 | Operating margin directly impacts profitability and EPS. The company anticipates negative factors to outweigh positives, making the actual margin outcome a key indicator of financial health and management's execution on efficiency. | Ticker | | | | | | | | | | | | | | | LULU (ticker) | LULU_94656df5 | 2025-12-11 | earnings_transcript |
| Lululemon's execution of its inventory management strategy, aiming to keep inventory units below sales and increase full-price penetration, leveraging chase capabilities to minimize markdown risk. | As we look out to next year, we are planning inventory units below sales. Our aim is to increase full price penetration and utilize our chase capabilities to minimize markdown risk. | 2026-02-02 | 2027-01-31 | Successful inventory management and higher full-price penetration will directly improve gross margins and reduce the need for markdowns, positively impacting profitability. | Ticker | | | | | | | | | | | | | | | LULU (ticker) | LULU_b4f77ec9 | 2025-12-11 | earnings_transcript |
| Testing and potential rollout of a re-architected 'Create Your Own' platform and clearly defined entry-price entrees across core menu categories. | later this year as we pace and sequence these moves over the next several quarters | 2026-03-01 | 2026-12-31 | These initiatives are designed to create a more transparent value ladder, improve value perception, and support incremental traffic and transactions across a broader range of price points, impacting sales and margins. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_11c24266 | 2026-02-26 | earnings_transcript |
| Optimization of the SG Rewards loyalty program, including improved perks, adding tiers, and boosting benefits. | later this year | 2026-03-01 | 2026-12-31 | This re-envisioning aims to increase customer frequency and spend through personalized messages and incentives, driving higher lifetime value among the most valuable guests. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_68882321 | 2026-02-26 | earnings_transcript |
| Opening of approximately 15 net new restaurants, with nearly half featuring Infinite Kitchen technology, and entry into two new markets (Nashville and Salt Lake City). | back half of the year | 2026-07-01 | 2026-12-31 | This unit growth contributes to revenue expansion, broadens market presence, and leverages Infinite Kitchen technology for improved throughput, order accuracy, and labor savings, impacting overall profitability. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_43e6699f | 2026-02-26 | earnings_transcript |
| Improvement in same-store sales trends, moving from an expected decline in Q1 (the most challenging quarter) to a more moderate decline or potential positive growth. | throughout the year | 2026-03-01 | 2026-12-31 | Same-store sales are a key indicator of business health and demand trajectory, directly impacting revenue, restaurant-level margins, and investor sentiment. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_40ee7341 | 2026-02-26 | earnings_transcript |
| Implementation and optimization of cost-saving initiatives, including streamlining ordering systems, supplier diversification, and improving operational efficiencies. | For 2026 | 2026-01-01 | 2026-12-31 | These efforts aim to improve restaurant-level margins and adjusted EBITDA by reducing food, beverage, packaging, and labor costs, contributing to a more resilient operating model. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_69af786d | 2026-02-26 | earnings_transcript |
| Reduction in underlying support center costs (G&A) to approximately 13% of revenue, down from 15.3% in 2025. | For 2026 | 2026-01-01 | 2026-12-31 | This streamlining of the organization and greater cost discipline directly impacts overall profitability and adjusted EBITDA by reducing overhead expenses. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_fd756f18 | 2026-02-26 | earnings_transcript |
| Performance of the national Wraps platform launch, including its impact on traffic, comparable sales, and customer retention. | Wraps now launched nationally | 2026-05-08 | 2026-12-31 | Successful adoption of Wraps is expected to drive incremental traffic from new and returning guests, expand occasions, and contribute to improved comparable sales and restaurant-level margins. Conversely, poor performance could exacerbate traffic declines and pressure profitability. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_e7776db9 | 2026-05-08 | earnings_transcript |
| Testing of a rearchitected pricing ladder, which includes the introduction of clear entry price points and a new 'Create Your Own' construct. | late June | 2026-06-20 | 2026-09-30 | This initiative aims to deliver greater price clarity and a more intuitive ordering experience, potentially supporting incremental transactions and improving value perception. The outcome of this test will guide future rollout decisions and could materially impact customer spending and revenue. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_536bdece | 2026-05-08 | earnings_transcript |
| Achievement of fiscal year 2026 guidance for same-store sales (decline of -4% to -2%), restaurant level margin (14.2% to 14.7%), and adjusted EBITDA ($1 million to $6 million). | fiscal year 2026 | 2026-05-08 | 2026-12-31 | Meeting or exceeding this guidance would signal successful execution of the 'Sweet Growth Transformation Plan' and operational improvements, which could positively impact investor sentiment and valuation. Missing guidance would indicate ongoing challenges and potentially pressure the stock. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_e99ef462 | 2026-05-08 | earnings_transcript |
| Introduction of new core and seasonal menu items, continued expansion of the Wraps platform, and upcoming collaborations with leading chefs. | for the balance of the year, including summer and fall menu updates | 2026-06-01 | 2026-12-31 | This ongoing menu innovation aims to keep the brand relevant, attract new guests, and drive repeat visits, contributing to top-line growth and strengthening the overall customer experience. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_eb79af86 | 2026-05-08 | earnings_transcript |
| Successful opening and performance of approximately 13 net new restaurants in 2026, with nearly half featuring the Infinite Kitchen technology. | this year | 2026-05-08 | 2026-12-31 | New unit growth, particularly with the more efficient Infinite Kitchens, is crucial for expanding Sweetgreen's footprint, driving revenue, and demonstrating the scalability and operational benefits of its technology, which can impact long-term growth prospects. | Ticker | | | | | | | | | | | | | | | SG (ticker) | SG_2e0d4535 | 2026-05-08 | earnings_transcript |
| Realization of systematic improvements in supply chain efficiency and reduction of total cost of delivered goods through efforts by R&D and supply chain organizations. | as we close out this fiscal year and move through fiscal year 2027 | 2026-06-01 | 2027-08-31 | This action aims to improve gross margins and overall profitability, but the actual magnitude and timing of savings are uncertain and dependent on fluctuating commodity costs. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_67fd24aa | 2026-04-09 | earnings_transcript |
| Implementation of pricing actions to offset cost inflation and a reduction in reliance on price promotion by eliminating low-returning customer spend. | in fiscal 2027 | 2026-09-01 | 2027-08-31 | This strategy intends to restore gross margins and rebalance investments towards brand building, but its success is subject to consumer elasticity, competitive response, and future inflation trends. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_1d040287 | 2026-04-09 | earnings_transcript |
| Strategic refocusing of marketing investment, innovation, and communication on Quest bars to strengthen core velocities and drive household penetration and buy rate. | moving forward | 2026-06-01 | 2027-08-31 | Quest is the primary growth engine for the company; successful reacceleration of bar growth is crucial for unlocking the brand's full potential and improving overall company performance. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_3aa9756d | 2026-04-09 | earnings_transcript |
| Completion of Atkins' retail distribution reset to a viable core assortment, which involves anticipated retail distribution losses. | in the near term, over the next year | 2026-04-09 | 2027-08-31 | This reset establishes a foundational, right-sized presence for the brand at retail, which is necessary before attempting to drive profitable growth and re-engage consumers. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_95fbff72 | 2026-04-09 | earnings_transcript |
| Development and implementation of a new positioning and investment strategy for Atkins, specifically investigating its role and messaging for GLP-1 users. | moving forward | 2026-04-09 | 2027-08-31 | This initiative aims to leverage the growing GLP-1 trend to potentially grow the Atkins consumer base again, but the success of this new strategy and consumer acceptance are uncertain. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_0e92250f | 2026-04-09 | earnings_transcript |
| Completion of OWYN's retail distribution reset due to poor velocities and subsequent restoration of disciplined growth through focused marketing and paced distribution expansion. | in the coming months, over the next year | 2026-04-09 | 2027-08-31 | This is crucial for OWYN to establish a stable base and then expand its reach in the plant-based protein segment, but the duration of the reset and effectiveness of new strategies are uncertain. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_52024ef9 | 2026-04-09 | earnings_transcript |
| Evolution of market prices for key commodities, particularly whey protein (currently at historic highs) and cocoa (expected savings starting in Q4 FY26 and best savings in FY27). | second half of this year and into fiscal '27 | 2026-06-01 | 2027-08-31 | Changes in these commodity costs directly impact gross margins and profitability; favorable trends could improve margins, while unfavorable trends could pressure them. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_dd7ebefd | 2026-04-09 | earnings_transcript |
| Implementation of a high single-digit price increase across most of The Simply Good Foods Company's portfolio. | effective in September | 2026-09-01 | 2026-09-30 | This pricing action is necessary to offset ongoing inflation in input costs and is expected to rebuild margins. However, management anticipates a volume impact due to elasticities, which could make the consumer dynamics of the turnaround more difficult. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_1284612e | 2026-07-09 | earnings_transcript |
| Expected distribution losses for OWYN products due to past product quality issues and ineffective marketing execution. | over the next 6-12 months | 2026-07-10 | 2027-07-10 | These losses will negatively impact OWYN's net sales and overall company performance in the near term as the company focuses on a distribution reset and refocusing on core products. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_cdcdfdcc | 2026-07-09 | earnings_transcript |
| Atkins brand is expected to see more favorable year-over-year comparisons in household penetration and distribution losses as the company laps prior year declines. | As we move into the fourth quarter and into next year | 2026-06-01 | 2027-08-31 | This stabilization is a key step in the Atkins turnaround, potentially leading to a reset of the retail baseline and creating an opportunity to rebuild the brand from a stronger foundation. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_db77a522 | 2026-07-09 | earnings_transcript |
| Market testing of new marketing ideas for Atkins, specifically leveraging insights from GLP-1 therapies and their impact on consumption behaviors. | as we move into the next fiscal year | 2026-09-01 | 2027-08-31 | This initiative aims to restore clarity around Atkins' consumer proposition and potentially grow household penetration by tapping into the GLP-1 weight management consumer segment, which could significantly impact the brand's future growth and profitability. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_9b0dcb73 | 2026-07-09 | earnings_transcript |
| Ongoing efforts to re-accelerate growth in Quest bars through improved top-of-funnel communication, innovation reflecting evolving consumer preferences, and appropriate marketing investment. | Re-accelerating growth in Quest bars is our highest priority | 2026-07-10 | 2027-08-31 | Quest bars represent a significant portion of the Quest brand, and their underperformance has impacted total brand buy rate. Successful re-acceleration is crucial for Quest's overall growth engine status and the company's top line. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_6d356fe9 | 2026-07-09 | earnings_transcript |
| Completion of OWYN's distribution reset and strategic refocusing of growth efforts on its core ready-to-drink and powder products. | Looking ahead, our priority is to complete the distribution reset and refocus OWYN growth on core ready-to-drink and powder business. | 2026-07-10 | 2027-07-10 | This action aims to stabilize OWYN's performance by addressing past execution issues and aligning with underlying consumer demand for clean label plant-based nutrition, which is critical for its long-term potential. | Ticker | | | | | | | | | | | | | | | SMPL (ticker) | SMPL_3fd93053 | 2026-07-09 | earnings_transcript |
| Readout of Foundayo Phase 3 trial in obstructive sleep apnea. | later this year | 2026-10-01 | 2026-12-31 | Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications. | Ticker | | | | | | | | | | | | | | | LLY (ticker) | LLY_48d9403d | 2026-08-05 | earnings_transcript |
| U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes. | later this year | 2026-10-01 | 2026-12-31 | This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth. | Ticker | | | | | | | | | | | | | | | LLY (ticker) | LLY_696cb569 | 2026-08-05 | earnings_transcript |
| Launch of Orforglipron in a few international markets (e.g., UAE). | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | | | | | | | | | | | | | | | LLY (ticker) | LLY_cf82d1b5 | 2026-02-04 | earnings_transcript |
| FDA regulatory decision for CagriSema in the U.S. for obesity. | at the end of 2026 | 2026-10-01 | 2026-12-31 | Approval would introduce a new, potentially highly effective obesity treatment, strengthening Novo Nordisk's pipeline and competitive position. | Ticker | | | | | | | | | | | | | | | NVO (ticker) | NVO_71e5b33d | 2026-05-06 | earnings_transcript |
| Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system. | by year end | 2026-10-01 | 2026-12-31 | This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins. | Ticker | | | | | | | | | | | | | | | DXCM (ticker) | DXCM_b887655c | 2026-07-30 | earnings_transcript |
| Opening of 7 new Life Time clubs. | in the fourth quarter | 2026-10-01 | 2026-12-31 | These new club openings are expected to contribute significantly to the company's revenue and adjusted EBITDA growth for late 2026 and into 2027. | Ticker | | | | | | | | | | | | | | | LTH (ticker) | LTH_38700d4e | 2026-07-30 | earnings_transcript |
| Eli Lilly's Q3 2026 earnings report will detail the initial impact of Medicare and Medicaid obesity coverage on the volume and pricing of GLP-1 medications. | Late October 2026 | 2026-10-29 | 2026-10-29 | The implementation of Medicare and Medicaid obesity coverage significantly expands the addressable market for GLP-1 medications, particularly for seniors, driving substantial volume growth for Eli Lilly and providing crucial insights into the financial trade-offs for expanded access across the 'medical optimization' segment. | Theme | theme_composer | LLY, NVO, HIMS | 3 | 13.005 | 1.18 | 1.05 | | 1.0 | 1611.3191 | 2026-09-01 | False | 1 | 0.687 | 85.1225 | Theme composer | | | |
| Eli Lilly's Q3 2026 earnings report will provide key updates on the U.S. launch trajectory and international rollout of Foundayo (Orforglipron), its oral GLP-1 medication. | Late October 2026 and ongoing into 2027 | 2026-10-29 | 2027-12-31 | Foundayo's successful uptake and global availability are vital for Lilly's volume-driven growth strategy and competitive positioning against rivals, significantly expanding the addressable market for obesity treatment by catering to patients who prefer oral medications, aligning with the theme's focus on convenient and effective solutions. | Theme | theme_composer | LLY, NVO, HIMS | 3 | 13.005 | 1.18 | 0.85 | | 1.0 | 1304.4012 | 2026-09-01 | False | 1 | 0.687 | 68.9087 | Theme composer | | | |
| CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings. | Theme | | | | | | | | | | | | | | | DXCM (ticker) | DXCM_80554779 | 2026-07-30 | earnings_transcript |
| Management target for the collective international business (inclusive of Eucalyptus) to reach break-even on an adjusted EBITDA basis within 12–18 months. | within 12 to 18 months | 2027-02-23 | 2027-08-23 | Achievement would validate international scaling playbook, reduce consolidated margin drag and accelerate path to 2030 EBITDA targets; failure to reach break-even would prolong international margin pressure and may require additional investment or slower expansion. | Ticker | | | | | | | | | | | | | | | HIMS (ticker) | HIMS_8ce0db05 | 2026-02-23 | earnings_transcript |
